Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov;17(6):783-790.
doi: 10.1016/j.jcf.2018.03.008. Epub 2018 Mar 23.

Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline

Christine L Chan  1 , Timothy Vigers  2 , Laura Pyle  3 , Philip S Zeitler  2 , Scott D Sagel  4 , Kristen J Nadeau  2
Affiliations

Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline

Christine L Chan et al. J Cyst Fibros. 2018 Nov.

Abstract

Background: To characterize glucose patterns with continuous glucose monitoring (CGM) in cystic fibrosis (CF) and assess relationships between CGM and clinical outcomes.

Methods: 110 CF youth and healthy controls (HC), 10-18 years, wore CGM up to 7 days. Correlations between CGM and lung function and BMI z-score change over the prior year were determined.

Results: Multiple CGM measures were higher in CF Normal Glycemic (CFNG) youth versus HC (peak glucose, excursions >140 mg/dl/day, %time > 140 mg/dl, standard deviation (SD) and mean amplitude of glycemic excursions (MAGE)). Hypoglycemia was no different among groups. In CF, decline in FEV1% and FVC% correlated with maximum CGM glucose, excursions >200 mg/dl/day, SD, and MAGE.

Conclusions: CFNG youth have higher glucoses and glucose variability than HC on CGM. Higher and more variable glucoses correlate with lung function decline. Whether earlier treatment of CGM abnormalities improves lung function in CF requires further study.

Keywords: Continuous glucose monitoring; Cystic fibrosis related diabetes; Pediatrics.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant conflicts of interest to disclose.

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

Comment in

References

    1. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697–708. - PMC - PubMed
    1. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(Suppl 1):S64–71. - PMC - PubMed
    1. Hardin DSGK, Baron B, Hale KA. Accelerated Red Blood Cell Turover Can Invalidate the Use of Hemoglobin A1c as a Diagnostic Test for Cystic Fibrosis Related Diabetes. The American Pediatric Society and the Society for Pediatric Research. 1999 May 4; 1999.
    1. Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros. 2013;12(4):318–31. - PubMed
    1. Lanng S, Hansen A, Thorsteinsson B, Nerup J, Koch C. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ. 1995;311(7006):655–9. - PMC - PubMed

Publication types

MeSH terms